Aries James, Montoto Silvia
Department of Haemato-oncology St Bartholomew's Hospital, Barts Health NHS Trust, 45 Little Britain, West Smithfield, EC1A 7BE, UK.
Curr Hematol Malig Rep. 2014 Sep;9(3):227-32. doi: 10.1007/s11899-014-0215-4.
Hodgkin lymphoma (HL) is more frequent in patients with Human Immunodeficiency Virus (HIV) infection than in immunocompetent patients. The relationship between the immune system and HL is complex. Whilst the incidence of HL in HIV patients has most likely increased since the introduction of combined anti-retroviral therapy (cART), there is no doubt that the outcomes for patients with HIV and HL (HIV-HL) have improved since its introduction. Improved CD4 counts and risk-adapted treatment schedules have resulted in outcomes for patients with HIV-HL that are comparable to those in HIV-negative patients with HL. Thus, HIV-HL should be treated in the same way as HL in immunocompetent patients, including the use of salvage chemotherapy and autologous transplant in the relapsed setting in HIV-HL. Along the same lines, patients with HIV-HL should not be excluded from trials based on their immune status alone.
霍奇金淋巴瘤（HL）在人类免疫缺陷病毒（HIV）感染患者中比在免疫功能正常的患者中更为常见。免疫系统与HL之间的关系很复杂。虽然自联合抗逆转录病毒疗法（cART）引入以来，HIV患者中HL的发病率很可能有所增加，但毫无疑问，自cART引入以来，HIV合并HL（HIV-HL）患者的治疗结果有所改善。CD4计数的改善和根据风险调整的治疗方案使得HIV-HL患者的治疗结果与HIV阴性的HL患者相当。因此，HIV-HL患者应与免疫功能正常的HL患者接受相同的治疗，包括在HIV-HL复发时使用挽救性化疗和自体移植。同样，HIV-HL患者不应仅因其免疫状态而被排除在试验之外。
